ESMO Congress 2026Developing

KRASCENDO

37 reports2 sourcesupdated 27 min ago

Start here

Synthesis

Roche has reported results from the Phase 3 Krascendo 1 trial of divarasib in previously treated advanced or metastatic non-small cell lung cancer with KRAS G12C mutations. The drug reduced the risk of death by 44% compared with existing KRAS G12C-targeted therapies. The findings position divarasib as a potential advance in a competitive KRAS G12C field. Full detailed data, regulatory filings and approval decisions have not yet been disclosed, so the drug's path to market remains open.

Written by a model from the reports · updated 3 hours ago

Latest developmentOct 27 01:40

Roche announced that divarasib cut the risk of death by 44% versus existing KRAS G12C therapies in the Phase 3 Krascendo 1 study.

Coverage timeline

Follow the coverage to see the different angles.

Oct 27

Oct 26

23:21
x.com
Divarasib extended median overall survival to 17.7 months vs 12.0 months with sotorasib or adagrasib in the Krascendo 1 trial, with new olomorasib and daraxonrasib data close behin
23:03
x.com
📍 Krascendo 1 🫁 #krasg12c #nsclc #esmo2026 #presidentialSymposium2
22:00
x.com
Original Article: Divarasib as Compared with Sotorasib or Adagrasib in 𝘒𝘙𝘈𝘚 G12C–Mutated NSCLC (phase 3 Krascendo 1 trial) https://nej.md/4BiCvbk
20:40
x.com
🔬 #ESMO26 | El Dr. @javierDcastro , presidente de @_SEOM, analiza KRASCENDO 1 (LBA5), presentado en la Sesión Presidencial del Congreso @myESMO 2026.
20:40
mp.weixin.qq.com
Roche divarasib cuts risk of death 44% in Krascendo 1 Phase 3 KRAS G12C advanced NSCLC study
Roche announced Phase 3 Krascendo 1 results for divarasib, showing a 44% reduction in the risk of death compared with existing KRAS G12C-targeted therapies in previously treated advanced or metastatic non-small cell lung cancer.
14:47
x.com
הנתונים החדשים מ־ #ESMO26 #ESMO2026
10:35
x.com
Krascendo 1 #ESMO26: divarasib vs sotorasib/adagrasib, pretreated KRAS G12C NSCLC
06:33
x.com
🚨 #ESMO26 | Phase III KRAScendo 1 demonstrates a major advance in previously treated KRAS G12C-mutant NSCLC.
05:28
x.com
KRAScendo 1: divarasib met its primary PFS endpoint and improved OS vs a sotorasib-dominant control.
04:03
x.com
📣 Presidential Symposium Spotlight 📣: Head-to-head vs sotorasib or adagrasib, divarasib improved PFS (9.8 vs 5.7 mo; HR, 0.58) and OS (HR, 0.56) in previously treated KRAS G12C–mut
03:37
x.com
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials in lung and gastrointestinal ca
01:09
x.com
🚨 Major KRAS G12C NSCLC results at #ESMO26!
00:01
x.com
KRAScendo 1: the first head-to-head comparison in KRAS G12C-targeted therapy, presented at ESMO and published in NEJM.
00:00
x.com
Brilliant discussion from Dr. @BenjaminBesseMD at #ESMO26 on the Krascendo 1 study of divarasib vs sotorasib/adagrasib. Rightly points out lack of crossover in a study with a PFS e

Oct 25

Oct 23

10:15
x.com
1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked. @myESMO

Oct 20

02:04
x.com
One of my most anticipated #ESMO26 presentations: Krascendo 1 (LBA5) — phase III divarasib vs sotorasib/adagrasib in previously treated KRAS G12C+ NSCLC. Roche reports positive P…

Heat trend for this story

Heat now 178·Peak in the comparable set 178 (Oct 27 02:00)·Change over 24h in the comparable set +13%·Participants now 30

Participants counted30

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.